Graf Acquisition Partners IV LLC - Dec 20, 2024 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)

Role: 10%+ Owner
Signature: /s/ James A. Graf, managing member of Graf Acquisition Partners IV LLC
Stock symbol: NKGN
Transactions as of: Dec 20, 2024
Transactions value $: $0
Form type: 4
Date filed: 12/26/2024, 07:20 PM
Previous filing: Dec 23, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NKGN	Common Stock	Other	$0	-63.6K	-2.97%	$0.00	2.08M	Dec 20, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NKGN	Private Placement Warrants	Disposed to Issuer		-758K	-39.81%		1.15M	Dec 20, 2024	Common Stock	758K	$11.50	Direct	F2, F3
transaction	NKGN	Working Capital Warrants	Disposed to Issuer		-93.3K	-49.17%		96.5K	Dec 20, 2024	Common Stock	93.3K	$11.50	Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 20, 2024, Graf Acquisition Partners IV LLC (the "Sponsor") distributed 63, 634 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") to Christine Low, Franklin FTX I, L.P., and Andrew Bail, each a member of the Sponsor and initially entitled to the distribution of 15% of the original shares of common stock held by the Sponsor, which were issued upon the conversion of the shares of Class B common stock of Graf Acquisition Corp. IV, upon September 29, 2024, the one-year anniversary of the closing of the business combination between Graf Acquisition Corp. IV and the Issuer, and the additional parties thereto.
F2	The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor.
F3	The Private Placement Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Private Placement Warrants were initially purchased at a price of $1.50 per Private Placement Warrant in accordance with the private placement warrant agreement between the Sponsor and the Issuer.
F4	The Working Capital Warrants were distributed by the Sponsor to its members in accordance with its limited liability company agreement, as amended. The Working Capital Warrants were issued in connection with the conversion of working capital loans, entered into between the Sponsor and the Issuer, at a price of $1.50 per Working Capital Warrant.